Bionoid Pharma, Inc. Rebrands as AI Maverick Intel, Inc. to Reflect Strategic Shift Toward AI-Driven Innovation
-
Arab, Muslim leaders urge review of Israel ties after Qatar attack
-
Mbappe 'not anxious' over Champions League goal as Bellingham returns
-
Huge pot of Nigerian jollof rice sets Guinness record
-
Heartbreak will help Arsenal's Champions League charge: Arteta
-
Europe stumped by Trump demands over Russia sanctions
-
Cycling fears spread of race-halting protests after Vuelta chaos
-
US, China reach 'framework' deal on TikTok ownership
-
'With our fists if necessary': Venezuelans prepare to defend homeland against potential US invasion
-
Duplantis thrives on Tokyo energy to break world record again
-
Ex-France defender Umtiti calls time on club career
-
One in six US parents rejecting standard vaccine schedule: poll
-
Sheffield Utd appoint Wilder for third managerial spell
-
UAE hammer Oman in Asia Cup to keep Super Four hopes alive
-
Activists on trial as France debates right to die
-
Duplantis reaches new heights, Beamish makes Kiwi history at worlds
-
Frank relishing Champions League debut with Spurs
-
Spanish PM calls for Israel to be barred from international sport
-
UK aristocrat, partner get 14 years for baby daughter's manslaughter
-
US says 'framework' deal with China on TikTok ownership
-
Shootings 'unjustified' in Bloody Sunday killings, Belfast court hears
-
Three French women accused of IS links go on trial
-
'Stoked' Beamish stuns tearful El Bakkali for world steeplechase gold
-
Israel attack aimed to halt Gaza talks, Qatar emir tells emergency summit
-
Stocks push higher ahead of expected US rate cut
-
Duplantis sets new pole vault record as retains world title
-
US announces 'framework' TikTok deal with China
-
Kiwi Beamish stuns tearful El Bakkali for world steeplechase gold
-
Mbappe not anxious over Champions League wait: Alonso
-
Japan medal hope Muratake relishing stage at Tokyo worlds
-
Right-to-die activists on trial in France as lawmakers debate end-of-life bill
-
Singing British hurdler Donovan in tune on world debut
-
'Multiple concussions' force France lock Willemse to retire
-
Athletic 'not afraid' of Arsenal on Champions League return: Inaki Williams
-
Hatton's family speak of 'immeasurable' loss after boxer's death
-
Rubio promises 'unwavering support' for Israel in Gaza goals
-
Stocks diverge ahead of expected US rate cut
-
Alfred out of world 200m with hamstring strain
-
Ex-British soldier goes on trial in landmark Bloody Sunday case
-
Pro-Palestinian protestors invading Vuelta course 'unacceptable': organisers
-
Fruit fly tests in Greece target invasive species threat
-
US 'very close' to TikTok deal with China: US Treasury chief
-
Paolini vows to 'fight until last ball' for BJK Cup glory
-
'Multiple concussions' forces France lock Willemse to retire
-
Rubio talks Gaza with Netanyahu after Qatar strike
-
Pakistan lodge protest as India tensions spill into cricket
-
German defence giant Rheinmetall to take over warship maker
-
Arab, Muslim leaders hold emergency talks after Israel's Qatar attack
-
Markets mixed ahead of expected US rate cut
-
Rubio takes up Qatar strike unease with Netanyahu
-
US-China trade talks resume in Madrid
NYSE - LSE
| RIO | 1.75% | 63.555 | $ | |
| BTI | -0.67% | 56.215 | $ | |
| NGG | -0.06% | 71.557 | $ | |
| CMSC | -0.23% | 24.305 | $ | |
| JRI | 0.06% | 14.105 | $ | |
| GSK | -1.13% | 40.375 | $ | |
| SCS | 0.24% | 16.85 | $ | |
| BCC | -0.63% | 85.14 | $ | |
| RYCEF | 1.41% | 15.64 | $ | |
| RBGPF | -1.67% | 76 | $ | |
| AZN | -1.95% | 78.036 | $ | |
| CMSD | 0.19% | 24.446 | $ | |
| VOD | -0.51% | 11.79 | $ | |
| BP | 0.95% | 34.215 | $ | |
| BCE | -2.31% | 23.615 | $ | |
| RELX | 0.81% | 46.88 | $ |
Bionoid Pharma, Inc. Rebrands as AI Maverick Intel, Inc. to Reflect Strategic Shift Toward AI-Driven Innovation
NEW YORK CITY, NEW YORK / ACCESS Newswire / May 16, 2025 / Bionoid Pharma Inc. (OTC PINK:BINP) proudly announces its corporate rebranding to AI Maverick Intel, Inc., marking a significant transformation in its strategic direction. This change underscores the company's commitment to leveraging advanced artificial intelligence technologies to revolutionize customer acquisition and engagement across healthcare, biotech, and other sectors.
The rebranding follows the successful acquisition of AI Maverick Intel, a leading platform renowned for its proprietary AI solutions that automate and enhance audience engagement. The platform's capabilities enable intelligent, two-way communication and data-driven interactions, positioning the company at the forefront of AI-driven business solutions.
"Our evolution into AI Maverick Intel, Inc. signifies more than a name change; it represents our dedication to pioneering AI technologies that drive meaningful engagement and sustainable growth," said Wayne Cockburn, CEO of AI Maverick Intel, Inc. "By integrating cutting-edge AI solutions, we are poised to deliver unparalleled value to our clients and stakeholders."
The company's flagship AI Maverick platform is designed to streamline customer acquisition processes, enabling businesses to identify, reach, and engage their target audiences with unprecedented efficiency and precision. This strategic shift aligns with the company's vision to become a leader in AI-driven solutions that foster innovation and long-term value creation.
For more information about AI Maverick Intel, Inc. and its innovative AI solutions, please visit https://aimaverickintel.com/
About Bionoid Pharma Inc.
Bionoid Pharma Inc. is a growth-oriented AI company focused on acquiring and enhancing revenue-generating businesses through its proprietary AI Maverick platform. The technology enables intelligent, two-way communication and data-driven engagement across healthcare, biotech, and other sectors. Bionoid aims to deliver long-term value through innovation, efficiency, and strategic partnerships.
Stay Connected:
Website | AI Maverick | OTC:BINP | X: @BionoidPharminc
Media Contact:
Wayne Cockburn, CEO
(905) 505-0770
Email: [email protected]
SOURCE: Bionoid Pharma Inc.
View the original press release on ACCESS Newswire
A.Jones--AMWN
